Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
139,800
Employees139,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
139,800
Employees139,800

JNJ Key Statistics

Market cap
526.85B
Market cap526.85B
Price-Earnings ratio
21.10
Price-Earnings ratio21.10
Dividend yield
2.35%
Dividend yield2.35%
Average volume
9.14M
Average volume9.14M
High today
$220.11
High today$220.11
Low today
$217.49
Low today$217.49
Open price
$219.20
Open price$219.20
Volume
10.02M
Volume10.02M
52 Week high
$220.11
52 Week high$220.11
52 Week low
$141.50
52 Week low$141.50

Stock Snapshot

As of today, Johnson & Johnson(JNJ) shares are valued at $218.75. The company's market cap stands at 526.85B, with a P/E ratio of 21.10 and a dividend yield of 2.4%.

On 2026-01-19, Johnson & Johnson(JNJ) stock traded between a low of $217.49 and a high of $220.11. Shares are currently priced at $218.75, which is +0.6% above the low and -0.6% below the high.

Johnson & Johnson(JNJ) shares are trading with a volume of 10.02M, against a daily average of 9.14M.

During the past year, Johnson & Johnson(JNJ) stock moved between $141.50 at its lowest and $220.11 at its peak.

During the past year, Johnson & Johnson(JNJ) stock moved between $141.50 at its lowest and $220.11 at its peak.

JNJ News

Nasdaq 8h
Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results?

Johnson & Johnson JNJ will begin the earnings season for the drug & biotech sector when it reports its fourth-quarter and full-year 2025 results on Jan. 21. The...

Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results?
TipRanks 9h
Looking for Exposure to Johnson & Johnson Stock ahead of Q4 Earnings? Here’s How to Buy Without the Risk

Johnson & Johnson (JNJ) is set to report its Q4 earnings on January 21. Analysts expect revenue of about $24.16 billion, up 7.3% year‑over‑year, and earnings of...

The Motley Fool 13h
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever

Income investors can rely on these stocks. "Set and forget" usually isn't the smartest investing strategy. Things could change with any company, causing you to...

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever

Analyst ratings

56%

of 27 ratings
Buy
55.6%
Hold
37%
Sell
7.4%

More JNJ News

TipRanks 16h
Is Johnson & Johnson Stock a Buy Ahead of Q4 Earnings?

Johnson & Johnson (JNJ) is scheduled to release its fourth-quarter fiscal 2025 results before the market opens on Wednesday, January 21. Analysts expect a sharp...

Simply Wall St 1d
ORIC Pharmaceuticals Is Up 32.5% After J&J Lung Cancer Collaboration and Pipeline Update - What's Changed

Earlier this month, ORIC Pharmaceuticals presented its oncology pipeline at the 44th Annual J.P. Morgan Healthcare Conference, highlighting progress on ORIC-944...

ORIC Pharmaceuticals Is Up 32.5% After J&J Lung Cancer Collaboration and Pipeline Update - What's Changed
Nasdaq 3d
June 2027 Options Now Available For Johnson & Johnson

Investors in Johnson & Johnson (Symbol: JNJ) saw new options begin trading today, for the June 2027 expiration. One of the key inputs that goes into the price a...

June 2027 Options Now Available For Johnson & Johnson
Simply Wall St 4d
Assessing ORIC Pharmaceuticals Valuation After Fresh Buy Ratings And Johnson & Johnson Collaboration

ORIC Pharmaceuticals (ORIC) stock has been in focus after fresh buy ratings from several research firms coincided with encouraging trial updates for its lead on...

Assessing ORIC Pharmaceuticals Valuation After Fresh Buy Ratings And Johnson & Johnson Collaboration
Simply Wall St 4d
Johnson & Johnson Is Up 5.3% After New TECVAYLI Phase 3 Myeloma Data - Has The Bull Case Changed?

Johnson & Johnson recently reported positive topline Phase 3 MajesTEC-9 results showing TECVAYLI monotherapy improved progression-free and overall survival vers...

Johnson & Johnson Is Up 5.3% After New TECVAYLI Phase 3 Myeloma Data - Has The Bull Case Changed?
Benzinga 4d
Johnson & Johnson Drug Slows Blood Cancer, Extends Survival In Pretreated Patients

Johnson & Johnson (NYSE:JNJ) shared topline results from the investigational Phase 3 MajesTEC-9 study of Tecvayli (teclistamab-cqyv) monotherapy for multiple my...

Johnson & Johnson Drug Slows Blood Cancer, Extends Survival In Pretreated Patients
Nasdaq 4d
Johnson & Johnson Reaches Analyst Target Price

In recent trading, shares of Johnson & Johnson (Symbol: JNJ) have crossed above the average analyst 12-month target price of $213.83, changing hands for $218.61...

Johnson & Johnson Reaches Analyst Target Price

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .